atural disease progress of Dupuytren's disease

Completed

• Conditions: Dupuytren's disease; fibromatosis palmaris; 10010761

• Registration Number: NL-OMON46937
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2023-03-20
• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 272

Inclusion Criteria

Presence of primary Dupuytren's disease

Exclusion Criteria

Patients who are incapable of giving informed consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The natural course of progression of Dupuytren*s disease, defined as the<br /><br>increase in size of nodules and cords in millimetres and/or increase of total<br /><br>passive extension deficit in degrees and/or a change in echogenicity of the<br /><br>nodules and/or a change in nodule hardness.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Patient questionnaire on functional complaints (URAM-scale DLV)<br /><br>- presence and course of recurrent disease, defined as the development or<br /><br>change iof nodules and cords in millimetres and/or increase of total passive<br /><br>extension deficit in degrees.<br /><br>- Echogenicity of the nodules<br /><br>- Hardness of the nodules</p><br>